Cargando…

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma

Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice question...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotoulas, Serafeim Chrysovalantis, Tsiouprou, Ioanna, Fouka, Eva, Pataka, Athanasia, Papakosta, Despoina, Porpodis, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878072/ https://www.ncbi.nlm.nih.gov/pubmed/35207654 http://dx.doi.org/10.3390/jpm12020165

Ejemplares similares

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2023)

Electronic Cigarettes and Asthma: What Do We Know So Far?
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2021)

Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice
por: Porpodis, Konstantinos, et al.
Publicado: (2022)

Smoking-Induced Disturbed Sleep. A Distinct Sleep-Related Disorder Pattern?
por: Grigoriou, Ioanna, et al.
Publicado: (2023)

Smoking and Obstructive Sleep Apnea: Is There An Association between These Cardiometabolic Risk Factors?—Gender Analysis
por: Ioannidou, Despoina, et al.
Publicado: (2021)

Recent insights in the role of biomarkers in severe asthma management
por: Fouka, Evangelia, et al.
Publicado: (2022)

Sleep During the COVID-19 Pandemic
por: Papagiouvanni, Ioanna, et al.
Publicado: (2022)

COVID-19 and liver injury: An ongoing challenge
por: Papagiouvanni, Ioanna, et al.
Publicado: (2023)

Cytokine gene polymorphisms in Greek patients with severe asthma
por: Papakosta, Despina, et al.
Publicado: (2015)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Acceptability of Healthcare Professionals to Get Vaccinated against COVID-19 Two Weeks before Initiation of National Vaccination
por: Pataka, Athanasia, et al.
Publicado: (2021)

Is it just an infection?
por: Pataka, Athanasia, et al.
Publicado: (2018)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Adherence to CPAP Treatment: Can Mindfulness Play a Role?
por: Pataka, Athanasia, et al.
Publicado: (2023)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
por: Ricciardi, Luisa, et al.
Publicado: (2022)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Α 78-year-old female who presents with a non-resolving pneumonia: what is your diagnosis?
por: Panagiotidou, Evangelia, et al.
Publicado: (2018)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
por: Humbert, Marc, et al.
Publicado: (2013)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome
por: JESENAK, MILOS, et al.
Publicado: (2020)

Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
por: Chong, Weikun, et al.
Publicado: (2023)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
por: Just, Jocelyne, et al.
Publicado: (2021)

Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape
por: Tsotsolis, Stavros, et al.
Publicado: (2023)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3clgudsm8imn2v1rii1jqaphie